XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Research Collaboration and License Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2017
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2018
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jul. 31, 2021
Jun. 30, 2019
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   $ 10,100,000 $ 12,100,000     $ 10,700,000 $ 12,500,000    
Collaboration contract asset and other assets   10,300,000       $ 10,800,000      
Revenue adjustments arising from contract modifications   (8,200,000)              
Pfizer, Inc.                  
Research Collaboration And License Agreements [Line Items]                  
Payments received   1,000,000 3,500,000 $ 28,000,000          
Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved               $ 1,400,000,000  
Pfizer, Inc. | Collaboration Agreement                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved               650,000,000  
Collaboration agreement direct and incremental costs incurred   12,900,000              
Collaboration contract asset and other assets   12,900,000              
Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved               400,000,000  
Payments received   0              
Pfizer, Inc. | Sales-Based Milestones                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved               $ 1,000,000,000  
Pfizer, Inc. | Development Milestone Payments | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   225,000,000              
Pfizer, Inc. | Sales Based Milestone Payments                  
Research Collaboration And License Agreements [Line Items]                  
Payments received   0              
Pfizer, Inc. | Sales Based Milestone Payments | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   550,000,000              
Pfizer, Inc. | Option Payments To License Agreement | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   37,500,000              
Bayer Collaboration Agreement                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved                 $ 17,500,000
Bayer Collaboration Agreement | Research Funding Payments                  
Research Collaboration And License Agreements [Line Items]                  
Payments received   1,500,000 $ 3,000,000            
Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast | Subsequent Event                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved         $ 12,000,000        
Bayer Collaboration Agreement | Development Milestone Payments                  
Research Collaboration And License Agreements [Line Items]                  
Payments received   0              
Bayer Collaboration Agreement | Development Milestone Payments | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved                 197,500,000
Bayer Collaboration Agreement | Sales Based Milestone Payments                  
Research Collaboration And License Agreements [Line Items]                  
Payments received   0              
Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved                 $ 490,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd.                  
Research Collaboration And License Agreements [Line Items]                  
Payments received $ 34,500,000                
Additional upfront non-refundable amount received under previous agreement $ 11,000,000                
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Related to Marketing Approvals                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   52,500,000              
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   44,000,000              
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones                  
Research Collaboration And License Agreements [Line Items]                  
Contract revenue receivable if milestones achieved   60,000,000              
Payments received   $ 0